Back to top

oncology-screening: Archive

Zacks Equity Research

OLMA Stock Soars 47% in September So Far on Second PFE Deal

Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.

AZNNegative Net Change NVSPositive Net Change PFENegative Net Change OLMANegative Net Change

Ahan Chakraborty

Will LLY's Oncology Portfolio Provide Key Diversification Benefits?

Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.

AZNNegative Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change